GCIHybridan Small Cap Feast: 10/07/24
* A corporate client of Hybridan LLP
** Arranged by type of listing and date of announcement
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced, or it is a rumour
Dish of the day
Delistings:
Gresham Technologies (GHT.L) has delisted from AIM
Partway Group (PTY.L) delisted from the Main market yesterday
What’s baking in the oven? **
Potential**** Initial Public Offerings:
ITF announced:
8th July 2024: Rome Resources: The Canada-based early-stage resource exploration Company has announced its intention to IPO on AIM in order to continue to make financial progress on its “Bisie North Tin Project”. The Company’s first day of trading on AIM is expected to be 26th July 2024. The Primary Offer expected size is approximately £4.0m.
24th June 2024: Rosebank Industries: The Company aims to repeat the successful 'Buy, Improve, Sell' business model which the Rosebank Co-Founders implemented during their time at Melrose. Rosebank proposes to acquire quality industrial or manufacturing businesses whose performance may be improved. The Company’s first day of trading on AIM is expected to be 11th July 2024. The Primary Offer expected size is approximately £50m.
Banquet Buffet***
The upstream oil and gas company focused on acquiring production and development assets in Africa have provided an operations and financial update for the 6 months ending 30 June 2024. Notably, the Company completed the Azule Acquisition in May 2024 for a net consideration of $28.4m, inheriting a crude oil stock of 480,000 barrels and driving commercial progress with a pre-tax revenue of $75.9m for 1H 2024 and cash resources of $13.8m. The strong liquidity position is expected to maintain steady operational improvement and provide a platform for further growth.
The distributed denial of service (DDoS) protection specialists focusing on defense solution and mitigation strategies has announced New Customer Wins continuing their robust 2024 customer acquisition momentum. Total contract values have reached $2.2m, including customers such as a top-10 US fiber provider (3-year deal with a $1m plus contract), a North American network neutral interconnection, co-location and data centre specialist and a Canadian major utility owned regional communications and internet service provider. The Company hope the new business momentum generated throughout Q2 2024 will provide a strong base from which they can further grow their global market presence and enhance their service offering.
The critical Healthcare communications technology developer announces a collaboration with a specialist clinical IT firm called Vertex with offices in the UK, UAE, and South Africa. The agreement enables the companies to work together and outlines the key terms which will form the basis of definitive commercial agreements for multiple collaborations. Vertex business is non-NHS and is FDA Cleared and CE Marked in other territories including the USA, Middle East and Europe. Feedback shares fell in April from 130p on a profits warning because of delays in the NHS procurement process. Consequently, its May 2023-24 revenues will be lower than expected at £1.2m and at the Interims to November 2023, announced in February this year, EBITDA losses increased 36% to £1.6m. Since then, a contract worth £0.5m was closed for its Bleepa product with an NHS Foundation Hospital and these delayed contracts are likely to be secured before the 2025 year-end according to management. There was around £4.3m in the bank at the end of April 2024 and finals to May 2024 are due to be reported in early September.
The specialist asset manager and investor focused on the transition to a more sustainable economy have reported both a quarterly financial update and an announcement of an agreement to acquire the European assets of SKY Harbor Capital Management (Assets under management of $2 billion). Post the completion of the SKY Harbor and Absalon acquisitions, Impax will have total fixed income assets under management and advice of approximately £3.1 billion as of 30 June 2024, providing a strong platform for the Company to expand its fixed income capabilities in the future.
The provider of high-speed packaging and automation solutions for the healthcare, food & beverage and clean energy sectors issued a trading update ahead of the release of its unaudited results for the six months ended 30 June 2024. H1 trading performance was in line with Board’s expectations as revenues are expected to increase by 15.5% from the previous year to $61m resulting in a June 2024 closing order book of circa £71m. Adam Holland, Chief Executive, is pleased that the Group has continued to gain momentum through the period and are well-placed to meet full year targets.
The workforce benefits and services provider aiming to improve employee health, wellbeing and engagement has announced the disposal of the entire issued share capital of Lets Connect IT Solutions to SME HCI Limited. The Company's technology salary sacrifice division was acquired for a total up front cash consideration of £2.0m on a cash-free, debt-free basis. Despite the business performing resiliently and in line with management's expectations for the year ended 31 December 2023, Let's Connect delivered turnover of £11.1m and £0.3m of profit before tax, the Board believes that its long-term performance will be optimised under the ownership of the Acquiror.
The supplier of innovative energy solutions for a cleaner planet focusing on the global power generation, shipping, industrial and refining industries have provided an update on its project with MSC Shipmanagement Limited of Cyprus. The Company moves closer to finalising the MSC marine project contract and once signed Quadrise equipment will be installed and commissioned at the facility in Antwerp prior to vessel trials. Quadrise are therefore ready to move quickly once the Project Agreement is sealed and make strong operational progress.
A clinical-stage biotechnology Company delivering targeted small molecules therapeutics to improve the treatment of cancer and autoimmune diseases announces certain management changes. Dr. Tim Mitchell, co-founder and Chief Executive Officer, will, after twenty years with the Company, transition to the part-time role of Chief Operating Officer and will continue to serve on the Board of Directors. Dr. Stephen Parker, currently Non-Executive Chairman, will assume the position of Executive Chairman on the Board whilst the Company seeks to appoint a new CEO at the appropriate time and as the future business strategy develops.
The venture capital fund that enables investors to gain access to early stage technology companies in the Augmented Reality & Virtual Reality market, Internet of Things and the Fintech industry have announced that Infinite Reality has agreed to acquire Landvault (a portfolio company of the Sure Valley Ventures Fund). It will be an all-share transaction valuing at $450m, where the disposal has the potential to generate proceeds for Sure Ventures PLC of circa $ 8.3 million. Sure Ventures PLC still own 25.9% of Sure Valley Ventures and will aim to maintain the same level of significant value creation in the future.
The UK energy exploration and production Company in the oil and gas industry has announced that it has raised gross proceeds of £0.5 million through a share placing of 3.33bn shares at a share price of 0.015 pence. The Placing represents a discount of approximately 28% per cent to the Closing Price of 0.021 pence and proceeds will be used for the termination of a convertible loan repaying in full the balance of the convertible funding facility with RiverFort Global Opportunities. Remaining funds may then be used to further the Company's material hydrogen storage projects and drive commercial progress by engaging with prospective strategic partners.
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.